How Saxenda works

Liraglutide acts on GLP-1 receptors involved in appetite and glucose control. You use Saxenda alongside a reduced-calorie diet and more physical activity. Treatment should support a health plan you can keep up. The goal is not to stop feeling hungry or to eat as little as possible. A review should cover how you feel and cope day to day, as well as weight and other health measures.

Who the adult licence covers

For adults, the UK licence covers a starting BMI of at least 30 kg/m², or at least 27 kg/m² with a weight-related condition such as dysglycaemia, high blood pressure, dyslipidaemia or obstructive sleep apnoea. Meeting the threshold does not make Saxenda right for you. Your clinician still checks your medical history, other medicines, pregnancy plans, risks and how well you are likely to tolerate treatment.

NHS access is narrower

NICE TA664 recommends Saxenda on the NHS for a smaller group than the licence covers. It sets specific BMI, blood glucose and heart risk criteria and needs a specialist service. Read it alongside current local arrangements and the policy in your UK nation. A private clinic's eligibility rules do not oblige your GP to prescribe or give an NHS service funding to start treatment.

A daily medicine with a set response check

Your dose goes up in steps to help your body adjust. For adults, the product information says to stop if you have not lost at least 5% of your starting weight after 12 weeks on the 3 mg daily dose. Count those 12 weeks from reaching 3 mg, not from your first starter injection. Children and adolescents have separate criteria. Adult rules do not carry over to paediatric care.

Other products contain liraglutide

Victoza is another liraglutide brand, made for type 2 diabetes, with different dosing. Liraglutide also appears in other presentations and combination products. Pens and licensed uses do not swap because the ingredient matches. Never use an insulin combination pen in place of a Saxenda pen. Check the brand and the full list of active ingredients.

Questions to take to your assessment

Ask what result would justify carrying on, how side effects will be handled, and what happens if treatment stops or becomes too expensive. Go over safe injection technique and sharps disposal. Get medical help for severe ongoing tummy pain, repeated vomiting or being unable to keep fluids down. A good plan also names the clinician in charge of follow-up, so each repeat prescription sits within ongoing care.

BMI is where the assessment starts

Two adults with the same BMI can have different medical histories, conditions and priorities. Your clinician may ask about recent weight change, eating difficulties, past treatments and anything limiting your daily life. The number opens the conversation. If you lose weight on treatment, you need a maintenance review. Your original reason for treatment does not vanish with the weight. Carrying on with treatment and starting treatment raise related but separate clinical questions.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. Saxenda: UK prescribing information medicines.org.uk
  2. NICE TA664: liraglutide for weight management nice.org.uk
  3. EMA: Victoza assessment and product information ema.europa.eu
  4. MHRA: GLP-1 medicines and rapid insulin reduction gov.uk

Spotted something out of date? Report a mistake.